BMRN

Biomarin Pharmaceutical Stock Analysis

AI Rating

Good
  • Quality7/10
  • Growth↑ 6/10
  • Value↓ 3/10
Biomarin Pharmaceutical sales and earnings growth
BMRN Growth
Good
  • Revenue Y/Y↑ 9.02%
  • EPS Y/Y↓ -49.09%
  • FCF Y/Y↑ 22.89%
Biomarin Pharmaceutical gross and profit margin trends
BMRN Profitability
Good
  • Gross margin ↑ 76.50%
  • EPS margin↓ 8.30%
  • ROIC 5Y↓ 7.62%
Biomarin Pharmaceutical net debt vs free cash flow
BMRN Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 17.8

Biomarin Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks